Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling

References

• Melberg H O, Lauritzen G, Ravndal E. Hvilken nytte, for hvem og til hvilken kostnad? En prospektiv studie av stoffmisbrukere i behandling [What benefit, for whom and to what cost? A prospective study of drug abusers in treatment]. Norwegian Institute for Drug and Alcohol Research, Oslo 2003
   Google Scholar
• Magura S, Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62–74
   PubMed Web of Science ®Google Scholar
• Milby J B. Methadone maintenance to abstinence. How many make it?. J Nerv Ment Dis 1988; 176: 409–422
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255–264
   PubMed Web of Science ®Google Scholar
• Sees K L, Delucchi K L, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA 2000; 283: 1303–1310
   PubMed Web of Science ®Google Scholar
• Bickel W K, Stitzer M L, Bigelow G E, Liebson I A, Jasinski D R, Johnson R E. A clinical trial of buprenorphine—comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43: 72–78
   PubMed Web of Science ®Google Scholar
• Millman R B, Khuri E T, Nyswander M E. Therapeutic detoxification of adolescent heroin addicts. Ann NY Acad Sci 1978; 311: 153–164
   PubMedGoogle Scholar
• Bickel W K, Amass L, Higgins S T, Badger G J, Esch R A. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 1997; 65: 803–810
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94: 1337–1347
   PubMed Web of Science ®Google Scholar
• Galanter M, Dermatis H, Resnick R, Maslansky R, Neumann E. Short-term buprenorphine maintenance: treatment outcome. J Addict Dis 2003; 22: 39–49
   PubMed Web of Science ®Google Scholar
• Petry N M, Bickel W K. Therapeutic alliance and psychiatric severity as predictors of completion of treatment for opioid dependence. Psychiatr Serv 1999; 50: 219–227
   PubMed Web of Science ®Google Scholar
• Resnick R B, Galanter M, Psycha C, Cohen A, Grandison P, Flood R. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 1992; 28: 109–113
   PubMed Web of Science ®Google Scholar
• Kornør H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev 2005; 24: 267–274
   PubMed Web of Science ®Google Scholar
• Bickel W K, Amass L. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 1995; 3: 477–489
   Web of Science ®Google Scholar
• Doran C M, Shanahan M, Mattick R P, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003; 71: 295–302
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews Issue 2 2003, CD002207
   Google Scholar
• Mattick R P, Ali R, White J M, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441–452
   PubMed Web of Science ®Google Scholar
• Walsh S L, Preston K L, Bigelow G E, Stitzer M L. Acute administration of buprenorphine in humans—partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361–372
   PubMed Web of Science ®Google Scholar
• Fudala P J, Jaffe J H, Dax E M, Johnson R E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525–534
   PubMed Web of Science ®Google Scholar
• Kosten T R, Krystal J H, Charney D S, Price L H, Morgan C H, Kleber H D. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990; 25: 73–78
   PubMedGoogle Scholar
• Jasinski D R, Pevnick J S, Griffith J D. Human pharmacology and abuse potential of analgesic buprenorphine—potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501–516
   PubMed Web of Science ®Google Scholar
• Breen C L, Harris S J, Lintzeris N, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend 2003; 71: 49–55
   PubMed Web of Science ®Google Scholar
• Seivewright N, Lagundoye O. Withdrawal from methadone and methadone for withdrawal. Methadone matters. Evolving community methadone treatment of opiate addiction, G Tober, J Strang. Martin Dunitz, London 2003; 79–90
   Google Scholar
• Ward J, Mattick R P, Hall W. How long is long enough? Answers to questions about the duration of methadone maintenance treatment. Methadone maintenance treatment and other opioid replacement therapies, J Ward, R P Mattick, W Hall. Harwood Academic Publishers, AmsterdamNetherlands 1998; 305–336
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Description and Diagnostic Guidlines. World Health Organization, Geneva 1992
   Google Scholar
• McLellan A T, Kushner H, Metzger D, et al. The 5th edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• Kokkevi A, Hartgers C. European Addiction Severity Index EuropASI. EuropASI Working Group, Zürich 1994, Cost A6
   Google Scholar
• Derogatis L R, Lipman R S, Rickels K, Uhlenhut E H, Covi L. Hopkins Symptom Checklist [HSCL]—self-report symptom inventory. Behav Sci 1974; 19: 1–15
   PubMedGoogle Scholar
• Millon T. The Millon inventories. Clinical and personality assessment. Guilford Press, New York 1997
   Google Scholar
• Robins L N, Wing J, Wittchen H U, et al. The Composite International Diagnostic Interview—an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988; 45: 1069–1077
   PubMed Web of Science ®Google Scholar
• SPSS for Windows, 11.0. SPSS Inc., Chicago 2001
   Google Scholar
• Joe G W, Simpson D D, Greener J M, Rowan-Szal G A. Integrative modeling of client engagement and outcomes during the first 6 months of methadone treatment. Addict Behav 1999; 24: 649–659
   PubMed Web of Science ®Google Scholar
• Krook A L, Brors O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002; 97: 533–542
   PubMed Web of Science ®Google Scholar
• Strain E C, Stitzer M L, Liebson I A, Bigelow G E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151: 1025–1030
   PubMed Web of Science ®Google Scholar
• Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002; 65: 283–290
   PubMed Web of Science ®Google Scholar
• Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick R P. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence [NEPOD]. Addiction 2004; 99: 450–460
   PubMed Web of Science ®Google Scholar
• Kosten T. Co-morbid depression and AIDS in opiate dependence: pharmacological treatments. Paper presented at the meeting of the International Society for Addiction Medicine, HelsinkiFinland, 2004
   Google Scholar
• Kanof P D, Aronson M J, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry 1993; 150: 423–428
   PubMed Web of Science ®Google Scholar
• Milby J B, Gentile M, Sims M K, McLellan A T, Woody G, Haas N. Methadone maintenance outcome as a function of detoxification fear: preliminary findings. NIDA Res Monogr 1991; 105: 589–590
   Google Scholar
• Eklund C, Hiltunen A J, Melin L, Borg S. Abstinence fear in methadone maintenance withdrawal: a possible obstacle for getting off methadone. Subst Use Misuse 1997; 32: 779–792
   PubMed Web of Science ®Google Scholar
• Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253–263
   PubMed Web of Science ®Google Scholar